Research programme: cerebral infarction therapeutic - Shin Nippon Biomedical/Nagasaki UniversityAlternative Names: Cerebroprotective peptide - Shin Nippon Biomedical Laboratories/Nagasaki University
Latest Information Update: 16 Jul 2016
At a glance
- Originator Nagasaki University School of Medicine; Shin Nippon Biomedical Laboratories
- Class Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebral infarction
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cerebral-infarction in Japan
- 21 Mar 2013 Preclinical trials in Cerebral infarction in Japan (unspecified route)